How to use stem cells for functional analysis and target discovery

stem cell, drug discovery, AstraZeneca, embryonic

Would an insight into the platforms being used for predictive toxicology and those used for safety screening be valuable to you?

Amy Pointon at AstraZeneca delivered a presentation highlighting just these topics during the Stem Cells for Drug Discovery Track at the 2012 World Stem Cell and Regenerative Medicine Congress .

Amy looked at;

  • recent advances in human embryonic and induced pluripotent stem cell technology and how it represents a new opportunity for assessing cardiac drug safety
  • developments of these systems to high through-put screening
  • the utility to provide mechanistic insight into toxicity and future advances

If you want to know the details DOWNLOAD the presentation today!

Do you want to know more?

Released: Post Event Report from 2012 World Stem Cells & Regenerative Medicine Congress

How to identify and validate drug toxicology

How to grow your business within the stem cell and regenerative medicine industry

Comments 1

  1. Paul Jones

    This research was paramount to our team’s characterisation of stem cells; especiailly around induced stem cell technology- pluripotent or otherwise.

    It is truly a pleasure to have worked with this researcher. She profoundly changed our opinions in the field.

Leave a Reply

Your email address will not be published. Required fields are marked *